- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03230812
Carnitine Supplementation in Type 2 Diabetic Patients
Carnitine Supplementation as a Therapy to Improve Insulin Sensitivity in Type 2 Diabetic Patients With Low Carnitine Status
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Type 2 diabetic patients are characterized by a decreased metabolic flexibility: a reduced capability to switch from fat oxidation in the basal state to carbohydrate oxidation in the insulin-stimulated state. This metabolic inflexibility is an early hallmark in the development of diabetes. Recent evidence suggests that a low carnitine availability may limit acetylcarnitine formation, thereby reducing metabolic flexibility. Thus, when substrate flux in the muscle is high, acetyl-CoA concentrations increase, leading to inhibition of pyruvate dehydrogenase (PDH) and thereby reducing glucose oxidation. The conversion of acetyl-CoA to acetylcarnitine relieves this acetyl-CoA pressure on PDH. In humans, carnitine supplementation is sometimes also beneficial, but not in everyone. Here we aim to test whether carnitine improves insulin sensitivity, furthermore, whether acetylcarnitine concentration at baseline or other characteristics are associated with the response (in insulin sensitivity) to carnitine supplementation. Furthermore, we will examine the potentially positive effect of carnitine supplementation in type 2 diabetes patients on intrahepatic lipid content, acetylcarnitine formation, blood plasma metabolites, body composition, physical performance and quality of life Objective: The primary objective is to investigate whether carnitine improves insulin sensitivity, furthermore, whether acetylcarnitine concentration at baseline or other characteristics are associated with the response (in insulin sensitivity) to carnitine supplementation. Furthermore, we will examine the potentially positive effect of carnitine supplementation in type 2 diabetes patients on intrahepatic lipid content, acetylcarnitine formation, blood plasma metabolites, body composition, physical performance and quality of life Study design: The current study is an interventional design with one study arm. Subjects will not be blinded for the intervention since all subjects will receive oral carnitine supplementation.
Study population: n=32, patient with type 2 diabetes (BMI 25-38, age 40-75 years) male and female will be included. Only subjects with relatively well-controlled non-insulin depended diabetes will be included.
Intervention (if applicable): Participants will be asked to take three chewing tablets of L-carnitine (330mg), three times a day (breakfast, lunch and dinner), for 96 days.
Main study parameters/endpoints: The primary study endpoints are insulin sensitivity and metabolic flexibility, measured by the hyperinsulinemic-euglycemic clamp. Secondary endpoints are maximal acetylcarnitine concentrations after exercise, Intrahepatic lipid content, body composition, metabolites in the blood before (i.e. glucose, free fatty acids, triglycerides, cholesterol, insulin), functional markers of physical performance, cognition, quality of life and quality of sleep.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229ER
- Maastricht University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and woman
- Age: 40-75 years
- Woman should be postmenopausal
- BMI: 25-38 kg/m2
- Stable dietary habits
- No use of medication interfering with investigated study parameters (as determined by responsible physician)
- Use of oral glucose lowering medication (metformin only or in combination with sulfonylurea agents)
Exclusion Criteria:
- Haemoglobin levels < 7.8 mmol/L
- Uncontrolled hypertension
- Use of anticoagulants
- Insulin dependent type 2 diabetic patients.
- No signs of active liver or kidney malfunction.
- Engagement in exercise > 3 hours a week
- Being vegetarian or vegan (because of altered whole body carnitine status)
- Alcohol and/or drug abuse
- Unstable body weight (weight gain or loss > 5kg in the last 3 months)
- Significant food allergies/intolerances (seriously hampering study meals)
- Participation in another biomedical study within 1 month before the first study visit, which would possibly hamper our study results
- Medication use known to hamper subject's safety during the study procedures
- Subjects with contra-indications for MRI
- Subjects who intend to donate blood during the intervention or subjects who have donated blood less than three months before the start of the study
- Subjects who do not want to be informed about unexpected medical findings
- No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: carnitine intervention (in all participants)
All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg.
Consumption of the chewing tablets will be divided over the day.
Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg).
Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
|
All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg.
Consumption of the chewing tablets will be divided over the day.
Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg).
Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin sensitivity
Time Frame: 2-step hyperinsulinemische-egulycemische clamp (5.5 hours)
|
Whole body insulin sensitivity measured as GIR in µmol/kg/min during the stable period of the insulin phase of the clamp.
|
2-step hyperinsulinemische-egulycemische clamp (5.5 hours)
|
Metabolic flexibility
Time Frame: 2-step hyperinsulinemische-egulycemische clamp (5.5 hours)
|
delta RER between basal and insulin stimulated state (both low (10mU) and high (40mU) insulin state
|
2-step hyperinsulinemische-egulycemische clamp (5.5 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal acetylcarnitine concentrations after exercise
Time Frame: 45 minutes
|
Measured using 1H-MRS after 30 minutes of cycling at 70% Wmax
|
45 minutes
|
Body composition (bod pod)
Time Frame: 30 minutes
|
determination fat mass and fat free mass
|
30 minutes
|
Intrahepatic lipid content
Time Frame: 45 minutes
|
Measured using 1H-MRS
|
45 minutes
|
physical performance
Time Frame: 6 minutes
|
distance covered in 6 minutes by walking
|
6 minutes
|
physical performance
Time Frame: 5 minutes
|
10 sit-standing exercises
|
5 minutes
|
Quality of life
Time Frame: 15 minutes
|
32-item questionnaire about Quality of Life.
Reporting happens via a score on the so called combined quality of life score scale.
The survey ranges between 32-160 points, with a higher score indicating a better QoL
|
15 minutes
|
Quality of sleep
Time Frame: 15 minutes
|
The Pittsburgh Sleep Quality Index (PSQI) was used to estimate quality of sleep (QoS) over the previous month.
Reporting happens via a score on the so quality of sleep score scale.
The score ranges between 0-21, with a lower score indicating a better sleep quality
|
15 minutes
|
Cognitive performance
Time Frame: 1 hour
|
CANTAB
|
1 hour
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal aerobic capacity
Time Frame: 20 minutes
|
(measured during a VO2max cycling test)
|
20 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vera Schrauwen, Dr, Maastricht University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL62791.068.17
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Intolerance
-
Yonsei UniversityNot yet recruitingType 2 Diabetes | Impaired Glucose Intolerance
-
University of California, IrvineUniversity of California, Davis; University of California, San FranciscoCompletedStress, Psychological | Pregnancy Related | Glucose Intolerance During PregnancyUnited States
-
Arizona State UniversityRecruiting
-
University of SaskatchewanRoyal University Hospital FoundationCompletedGlucose IntoleranceCanada
-
Glycemic Index Laboratories, IncDSM Nutritional Products, Inc.Completed
-
Materia Medica HoldingCompletedImpaired Glucose ToleranceRussian Federation
-
Joslin Diabetes CenterCompleted
-
TakedaCompletedImpaired Glucose ToleranceJapan
-
China Academy of Chinese Medical SciencesUnknownImpaired Glucose Tolerance
-
University of TromsoCompleted
Clinical Trials on Carnitene (L-Carnitine or Levocarnitine)
-
Montefiore Medical CenterThe Gerber FoundationCompletedPrematurity | Neurodevelopmental Disorder | Carnitine DeficiencyUnited States
-
Karen Lindhardt MadsenRigshospitalet, DenmarkCompletedCarnitine Transporter, Plasma-membrane, Deficiency of
-
Dr. Amer JohriQueen's University; Heart and Stroke Foundation of CanadaCompleted
-
Stanford UniversityNational Cancer Institute (NCI)CompletedMusculoskeletal ComplicationsUnited States
-
International Centre for Diarrhoeal Disease Research...CompletedMalnutritionBangladesh
-
University of GuadalajaraUnknownBody Weight ChangesMexico
-
Maastricht University Medical CenterTerminated
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic Leukemia | HyperbilirubinemiaUnited States